Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients

Authors: Katia Danza, Simona De Summa, Brunella Pilato, Massimo Carella, Orazio Palumbo, Ondina Popescu, Angelo Paradiso, Rosamaria Pinto, Stefania Tommasi

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The role of miRNAs in familial breast cancer (fBC) is poorly investigated as also in the BRCA-like tumors. To identify a specific miRNA expression pattern which could allow a better fBC classification not only based on clinico-pathological and immunophenotypical parameters we analyzed miRNA profile in familial and sporadic samples. Moreover since BRCA1 tumors and sporadic triple negative (TN) breast tumors share similarities regarding clinical outcomes and some histological characteristics, we focused on TN and not TN cases.

Methods

The sample set included fresh frozen tissue samples, including 39 female fBCs (19 BRCA-related and 20 BRCAX) and 12 male fBC (BRCAX). Moreover, we considered TN and non TN (NTN), 21 BRCA-related and 27 sporadic BCs. MiRNA profiling was performed through GeneChip miRNA v.1.0 Array (Affymetrix). ANOVA, hierarchical and consensus clustering analyses allowed identification of pattern of expression of miRNAs and pathway enrichment analysis, considering validated target genes, was carried out to achieve a deeper biological understanding.

Results

ANOVA test led to the identification of 53 deregulated miRNAs; hierarchical and consensus clustering of female fBCs (fFBCs) and male fBCs (fMBCs) highlighted the presence of 3 sample clusters named FBC1, FBC2 and FBC3. We found a correlation between ER-status and the three sample clusters. The three clusters are distinct by a different expression of two clusters of miRNAs (CLU1 and CLU2), which resulted to be different in targeted pathways. In particular, CLU1 targets cellular pathways and CLU2 is involved in epigenetic activities. Considering TN and NTN BRCA-related and sporadic tumors, a hierarchical clustering identified two clusters of miRNAs, which were not so different from CLU1 and CLU2, both in miRNA content and targeted pathways.

Conclusions

Our results highlighted the importance of miRNA regulation to better clarify similarities and differences between familial and sporadic BC groups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Melchor L, Benitez J: The complex genetic landscape of familial breast cancer. Hum Genet. 2013, 132 (8): 845-863. 10.1007/s00439-013-1299-y.CrossRefPubMed Melchor L, Benitez J: The complex genetic landscape of familial breast cancer. Hum Genet. 2013, 132 (8): 845-863. 10.1007/s00439-013-1299-y.CrossRefPubMed
4.
go back to reference Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 2011, 12 (12): 861-874. 10.1038/nrg3074.CrossRefPubMed Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 2011, 12 (12): 861-874. 10.1038/nrg3074.CrossRefPubMed
5.
go back to reference Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K: Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PloS one. 2013, 8: e55910-10.1371/journal.pone.0055910.PubMedCentralCrossRefPubMed Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K: Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PloS one. 2013, 8: e55910-10.1371/journal.pone.0055910.PubMedCentralCrossRefPubMed
6.
go back to reference Guo L, Zhao Y, Yang S, Cai M, Wu Q, Chen F: Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer. Mol Biol Rep. 2013, 40 (3): 2175-2186. 10.1007/s11033-012-2277-5.CrossRefPubMed Guo L, Zhao Y, Yang S, Cai M, Wu Q, Chen F: Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer. Mol Biol Rep. 2013, 40 (3): 2175-2186. 10.1007/s11033-012-2277-5.CrossRefPubMed
7.
go back to reference Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012, 109 (8): 3024-3029. 10.1073/pnas.1200010109.PubMedCentralCrossRefPubMed Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012, 109 (8): 3024-3029. 10.1073/pnas.1200010109.PubMedCentralCrossRefPubMed
9.
go back to reference Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S: Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol. 2013, 228 (6): 1264-1269. 10.1002/jcp.24281.CrossRefPubMed Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S: Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol. 2013, 228 (6): 1264-1269. 10.1002/jcp.24281.CrossRefPubMed
10.
go back to reference Tanic M, Yanowsky K, Rodriguez-Antona C, Andres R, Marquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B: Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One. 2012, 7 (6): e38847-10.1371/journal.pone.0038847.PubMedCentralCrossRefPubMed Tanic M, Yanowsky K, Rodriguez-Antona C, Andres R, Marquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B: Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One. 2012, 7 (6): e38847-10.1371/journal.pone.0038847.PubMedCentralCrossRefPubMed
11.
go back to reference Tanic M, Andres E, Rodriguez-Pinilla SM, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benitez J, Martinez-Delgado B: MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer. 2013, 109 (10): 2724-2734. 10.1038/bjc.2013.612.PubMedCentralCrossRefPubMed Tanic M, Andres E, Rodriguez-Pinilla SM, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benitez J, Martinez-Delgado B: MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer. 2013, 109 (10): 2724-2734. 10.1038/bjc.2013.612.PubMedCentralCrossRefPubMed
12.
go back to reference Murria Estal R, Palanca Suela S, de Juan Jimenez I, Egoavil Rojas C, Garcia-Casado Z, Juan Fita MJ, Sanchez Heras AB, Segura Huerta A, Chirivella Gonzalez I, Sanchez-Izquierdo D, Llop Garcia M, Barragan Gonzalez E, Bolufer Gilabert P: MicroRNA signatures in hereditary breast cancer. Breast Canc Res Treat. 2013, 142: 19-30. 10.1007/s10549-013-2723-7.CrossRef Murria Estal R, Palanca Suela S, de Juan Jimenez I, Egoavil Rojas C, Garcia-Casado Z, Juan Fita MJ, Sanchez Heras AB, Segura Huerta A, Chirivella Gonzalez I, Sanchez-Izquierdo D, Llop Garcia M, Barragan Gonzalez E, Bolufer Gilabert P: MicroRNA signatures in hereditary breast cancer. Breast Canc Res Treat. 2013, 142: 19-30. 10.1007/s10549-013-2723-7.CrossRef
13.
go back to reference Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004, 4 (10): 814-819. 10.1038/nrc1457.CrossRefPubMed Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004, 4 (10): 814-819. 10.1038/nrc1457.CrossRefPubMed
14.
go back to reference Turner NC, Reis-Filho JS: Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006, 25 (43): 5846-5853. 10.1038/sj.onc.1209876.CrossRefPubMed Turner NC, Reis-Filho JS: Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006, 25 (43): 5846-5853. 10.1038/sj.onc.1209876.CrossRefPubMed
15.
go back to reference Hill L, Browne G, Tulchinsky E: ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Canc J Int Canc. 2013, 132: 745-754. 10.1002/ijc.27708.CrossRef Hill L, Browne G, Tulchinsky E: ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Canc J Int Canc. 2013, 132: 745-754. 10.1002/ijc.27708.CrossRef
17.
go back to reference Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J: TM4: a free, open-source system for microarray data management and analysis. BioTechniques. 2003, 34: 374-378.PubMed Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J: TM4: a free, open-source system for microarray data management and analysis. BioTechniques. 2003, 34: 374-378.PubMed
18.
go back to reference Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001, 125 (1-2): 279-284. 10.1016/S0166-4328(01)00297-2.CrossRefPubMed Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001, 125 (1-2): 279-284. 10.1016/S0166-4328(01)00297-2.CrossRefPubMed
19.
go back to reference Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP: GenePattern 2.0. Nat Genet. 2006, 38 (5): 500-501. 10.1038/ng0506-500.CrossRefPubMed Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP: GenePattern 2.0. Nat Genet. 2006, 38 (5): 500-501. 10.1038/ng0506-500.CrossRefPubMed
20.
go back to reference Yitzhaki S: Gini’s mean difference: a superior measure of variability for non-normal distributions. METRON Int J Stat. 2003, LXI: 285-316. Yitzhaki S: Gini’s mean difference: a superior measure of variability for non-normal distributions. METRON Int J Stat. 2003, LXI: 285-316.
21.
go back to reference Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, Gerangelos S, Koziris N, Dalamagas T, Hatzigeorgiou AG: TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012, 40 (Database issue): D222-D229. 10.1093/nar/gkr1161.PubMedCentralCrossRefPubMed Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, Gerangelos S, Koziris N, Dalamagas T, Hatzigeorgiou AG: TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012, 40 (Database issue): D222-D229. 10.1093/nar/gkr1161.PubMedCentralCrossRefPubMed
22.
go back to reference Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC, Huang HD: miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014, 42: D78-D85. 10.1093/nar/gkt1266.PubMedCentralCrossRefPubMed Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC, Huang HD: miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014, 42: D78-D85. 10.1093/nar/gkt1266.PubMedCentralCrossRefPubMed
23.
go back to reference Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009, 37 (Database issue): D105-D110. 10.1093/nar/gkn851.PubMedCentralCrossRefPubMed Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009, 37 (Database issue): D105-D110. 10.1093/nar/gkn851.PubMedCentralCrossRefPubMed
24.
go back to reference da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4 (1): 44-57. 10.1038/nprot.2008.211.CrossRefPubMed da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4 (1): 44-57. 10.1038/nprot.2008.211.CrossRefPubMed
25.
go back to reference Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Canc Res. 2005, 65: 7065-7070. 10.1158/0008-5472.CAN-05-1783.CrossRef Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Canc Res. 2005, 65: 7065-7070. 10.1158/0008-5472.CAN-05-1783.CrossRef
26.
go back to reference Garcia-Becerra R, Santos N, Diaz L, Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012, 14 (1): 108-145. 10.3390/ijms14010108.PubMedCentralCrossRefPubMed Garcia-Becerra R, Santos N, Diaz L, Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012, 14 (1): 108-145. 10.3390/ijms14010108.PubMedCentralCrossRefPubMed
27.
go back to reference Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Canc Res. 2009, 11: R27-10.1186/bcr2257.CrossRef Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Canc Res. 2009, 11: R27-10.1186/bcr2257.CrossRef
28.
go back to reference Zhou J, Teng R, Wang Q, Xu C, Guo J, Yuan C, Shen J, Hu W, Wang L, Xie S: Endocrine resistance in breast cancer: current status and a perspective on the roles of miRNAs (review). Oncol Lett. 2013, 6 (2): 295-305.PubMedCentralPubMed Zhou J, Teng R, Wang Q, Xu C, Guo J, Yuan C, Shen J, Hu W, Wang L, Xie S: Endocrine resistance in breast cancer: current status and a perspective on the roles of miRNAs (review). Oncol Lett. 2013, 6 (2): 295-305.PubMedCentralPubMed
29.
go back to reference Zhou W, Slingerland JM: Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014, 14 (1): 26-38. 10.1038/nrc3622.CrossRefPubMed Zhou W, Slingerland JM: Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014, 14 (1): 26-38. 10.1038/nrc3622.CrossRefPubMed
30.
go back to reference Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S, Kumar R: Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev. 2013, 34 (1): 1-32. 10.1210/er.2011-1057.PubMedCentralCrossRefPubMed Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S, Kumar R: Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev. 2013, 34 (1): 1-32. 10.1210/er.2011-1057.PubMedCentralCrossRefPubMed
31.
go back to reference Hossain A, Kuo MT, Saunders GF: Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006, 26 (21): 8191-8201. 10.1128/MCB.00242-06.PubMedCentralCrossRefPubMed Hossain A, Kuo MT, Saunders GF: Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006, 26 (21): 8191-8201. 10.1128/MCB.00242-06.PubMedCentralCrossRefPubMed
32.
go back to reference Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH: Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol. 2011, 68 (3): 753-761. 10.1007/s00280-010-1548-x.CrossRefPubMed Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH: Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol. 2011, 68 (3): 753-761. 10.1007/s00280-010-1548-x.CrossRefPubMed
33.
go back to reference Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121 (7): 2750-2767. 10.1172/JCI45014.PubMedCentralCrossRefPubMed Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121 (7): 2750-2767. 10.1172/JCI45014.PubMedCentralCrossRefPubMed
34.
go back to reference Burgess M, Puhalla S: BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different. Front Oncol. 2014, 4: 19-PubMedCentralPubMed Burgess M, Puhalla S: BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different. Front Oncol. 2014, 4: 19-PubMedCentralPubMed
35.
go back to reference Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T: MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Canc Res. 2011, 71: 4443-4453. 10.1158/0008-5472.CAN-11-0608.CrossRef Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T: MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Canc Res. 2011, 71: 4443-4453. 10.1158/0008-5472.CAN-11-0608.CrossRef
36.
go back to reference Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D'Amico C, Paradiso A, Tommasi S: Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Canc Res Treat. 2011, 125: 651-657. 10.1007/s10549-010-0861-8.CrossRef Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D'Amico C, Paradiso A, Tommasi S: Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Canc Res Treat. 2011, 125: 651-657. 10.1007/s10549-010-0861-8.CrossRef
37.
go back to reference Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007, 26: 2126-2132. 10.1038/sj.onc.1210014.CrossRefPubMed Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007, 26: 2126-2132. 10.1038/sj.onc.1210014.CrossRefPubMed
38.
go back to reference Muggia F, Safra T: ‘BRCAness‘ and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014, 34 (2): 551-556.PubMedCentralPubMed Muggia F, Safra T: ‘BRCAness‘ and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014, 34 (2): 551-556.PubMedCentralPubMed
Metadata
Title
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients
Authors
Katia Danza
Simona De Summa
Brunella Pilato
Massimo Carella
Orazio Palumbo
Ondina Popescu
Angelo Paradiso
Rosamaria Pinto
Stefania Tommasi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-014-0319-6

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.